Wellington Management Group LLP Has $752.51 Million Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Wellington Management Group LLP boosted its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 9.0% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 4,076,426 shares of the medical research company’s stock after purchasing an additional 335,658 shares during the period. Wellington Management Group LLP owned approximately 0.08% of Charles River Laboratories International worth $752,508,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Versant Capital Management Inc lifted its holdings in shares of Charles River Laboratories International by 1,071.4% in the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after purchasing an additional 150 shares in the last quarter. Pinnacle Bancorp Inc. increased its position in shares of Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 65 shares during the last quarter. Tortoise Investment Management LLC increased its stake in shares of Charles River Laboratories International by 77.7% during the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company’s stock worth $49,000 after purchasing an additional 115 shares during the last quarter. ORG Wealth Partners LLC purchased a new position in shares of Charles River Laboratories International during the 4th quarter valued at $56,000. Finally, Wilmington Savings Fund Society FSB purchased a new stake in Charles River Laboratories International during the third quarter valued at about $59,000. Institutional investors own 98.91% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on CRL shares. Redburn Atlantic upgraded Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 price target on the stock in a research report on Monday, March 3rd. William Blair downgraded Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 22nd. The Goldman Sachs Group cut Charles River Laboratories International from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $190.00 to $170.00 in a research note on Friday, March 21st. Citigroup upgraded shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and upped their price target for the company from $155.00 to $175.00 in a report on Tuesday, March 4th. Finally, Morgan Stanley cut their price objective on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 5th. One analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the stock. According to MarketBeat.com, Charles River Laboratories International has a consensus rating of “Hold” and an average target price of $189.77.

Charles River Laboratories International Trading Down 3.2 %

Shares of NYSE CRL opened at $150.58 on Tuesday. Charles River Laboratories International, Inc. has a twelve month low of $146.64 and a twelve month high of $273.32. The firm has a market cap of $7.70 billion, a PE ratio of 1,003.89, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The business has a fifty day simple moving average of $164.43 and a two-hundred day simple moving average of $182.29. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. During the same period in the previous year, the company posted $2.46 earnings per share. The firm’s quarterly revenue was down 1.1% on a year-over-year basis. Analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Insider Transactions at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 4,400 shares of the firm’s stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the transaction, the executive vice president now owns 20,013 shares in the company, valued at $3,252,112.50. This trade represents a 18.02 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Birgit Girshick purchased 1,514 shares of the company’s stock in a transaction on Thursday, February 20th. The shares were purchased at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the purchase, the chief operating officer now owns 55,058 shares in the company, valued at approximately $9,064,198.54. The trade was a 2.83 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 1.30% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).